pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
Cell therapy for Inclusion Body Myositis (IBM... for Inclusion Body Myositis
Phase 2 · other · Inclusion Body Myositis
Cell therapy for Inclusion Body Myositis (IBM... for Inclusion Body Myositis for Inclusion Body Myositis is a Phase 2 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- other
- Indication
- Inclusion Body Myositis
- Status
- active
- Trials
- 1